



MPCCC

Monash Partners Comprehensive Cancer Consortium

STRATEGIC PLAN 2021-2025

ACKNOWLEDGEMENTS

The Monash Partners Comprehensive Cancer Consortium (MPCCC) would like to acknowledge the stakeholders who have given their time to attend focus groups, consultations and workshops and have provided valuable insights that have contributed to this strategic plan.

Key groups consulted included:

- MPCCC partner organisation Chief Executives
- MPCCC Governance Group
- MPCCC Executive Group
- MPCCC Advisory Group
- Monash Partners Academic Health Science Centre (Monash Partners)
- Southern Melbourne Integrated Cancer Service
- Research and clinical representatives from MPCCC Partner organisations: Monash University, Monash Health (Clayton and Moorabbin), Hudson Institute of Medical Research, Cabrini Health, Eastern Health, Epworth Healthcare, Peninsula Health, Alfred Health, Latrobe Regional Hospital
- Victorian Department of Health
- Victorian Comprehensive Cancer Centre Alliance (VCCC Alliance)
- Cancer Council Victoria
- People affected by cancer in our community


MPCCC also acknowledges expertise and direction provided by:

- Heather Wellington, Ngamuru Consulting
- Janet Cameron, Ngamuru Consulting
- Laura Porter, Nous Group
- Tom King, Nous Group

CONTENTS

ACKNOWLEDGEMENTS.....	2
CONTENTS	3
PLAN AT A GLANCE.....	4
THE CANCER, HEALTH AND RESEARCH ENVIRONMENT.....	5
ABOUT MONASH PARTNERS COMPREHENSIVE CANCER CONSORTIUM	6
OUR PARTNERS.....	7
PEOPLE AFFECTED BY CANCER IN OUR COMMUNITY	9
OUR AMBITION.....	11
OUR CHALLENGES AND OPPORTUNITIES	12
OUR FUTURE GOVERNANCE MODEL.....	14
OUR STAKEHOLDER ENGAGEMENT.....	15
OUR STRATEGIC PRIORITIES	16
PRIORITY 1: GOVERNANCE	17
PRIORITY 2: EDUCATION AND COMMUNICATION	18
PRIORITY 3: PRECISION CANCER PROGRAM.....	19
PRIORITY 4: CLINICAL TRIALS.....	20
MEASURING OUR SUCCESS	21
INDICATIVE BUDGET 2021-2025.....	22
APPENDIX I: ABOUT OUR PARTNERS.....	23
APPENDIX II: OUR RESEARCH	28
APPENDIX IV: ABBREVIATIONS	30

PLAN AT A GLANCE

Our vision			
To advance cancer care through world class research			
Our values			
Collaboration	Engagement	Innovation	Equity
Our contributing partners		Our participating partners	
Alfred Health, Eastern Health, Monash Health, Peninsula Health, Monash University (including the Hudson Institute of Medical Research).		Cabrini Health, Epworth Healthcare, Latrobe Regional Hospital.	
Our strategic priorities		Our approach	
		<ul style="list-style-type: none"> • support our partner organisations to share their resources and expertise • drive innovative and collaborative models of research and research-informed care • enable access to new research platforms and resources • build the capability of cancer clinicians, researchers and consumers • work to achieve equity of opportunity for consumers to participate in research and to access research-informed care • work cooperatively with other organisations on programs and projects of shared relevance 	
Our strategic policy alignment			
Victorian Cancer Plan 2020-2024		VicHealth Research Strategy 2020-2023	
Benefits of our collaboration			
Working at scale	Linking ideas & resources	Sharing & learning	Strengthening capability
Our impact			
World-class, patient-centred cancer research			
Improved prevention, diagnosis and treatments for people with cancer			

THE CANCER, HEALTH AND RESEARCH ENVIRONMENT

This MPCCC strategic plan 2021-2025 aligns with the policy directions laid out by the Victorian Government, the cancer research priorities of our contributing partner organisations, as well as emerging national health and research agendas being led by Cancer Australia.

Government policy directions include:

- [Victorian Cancer Plan 2020-2024: Improving Cancer Outcomes for all Victorians](#)
- [VicHealth Research Strategy 2020-2023](#)
- directions for quality improvement through [Safer Care Victoria](#)
- [Victorian Integrated Cancer Service priorities 2021-2022](#)
- initial themes identified for development of the [Australian Cancer Plan](#)

Partner strategies include:

- [The Alfred Cancer Strategy 2020-2025](#)
- [Eastern Health Research Plan 2019-2023](#)
- Monash Health [Strategic Plan 2023](#)
- Peninsula Health [Research Strategic Plan 2020-2024](#)
- [The Cancer Discovery Program](#), Monash Biomedicine Discovery Institute, Monash University
- [Central Clinical School](#), Monash University
- [School of Public Health and Preventive Medicine](#), Monash University
- [School of Clinical Sciences at Monash Health](#), Monash University
- [Eastern Health Clinical School](#), Monash University
- the vision and strategic agenda of the [Monash Partners Academic Health Science Centre](#)

ABOUT MONASH PARTNERS COMPREHENSIVE CANCER CONSORTIUM

The Monash Partners Comprehensive Cancer Consortium (MPCCC) is a strategic alliance of health services and research organisations working in partnership to advance cancer care through integrated, collaborative and innovative research.

The MPCCC represents a research network of over 2000 academic, clinical and health services researchers and those in our community who are affected by cancer.

The benefits of strategic collaboration across MPCCC partners include:

- **working at scale:** supporting cross-organisational research projects that benefit from partnership-wide input
- **linking ideas and resources:** fostering collaboration and links between partner organisations to generate ideas and direct resources to priority research
- **sharing and learning:** propagating and promoting the translation of basic, clinical and health services research into clinical practice to drive improvements in patient outcomes
- **strengthening world-class capability:** creating an integrated culture of cancer research led by clinicians and researchers and informed by community need.

Our achievements

MPCCC has enabled research-active professionals and people with cancer, to connect with each other and work collaboratively on innovative, patient-centred cancer research. This has been achieved through our maturing governance, research committees and teams, seminars, early to mid-career research awards, communications and networking events. Annual travel grants, poster prizes and an award for research excellence have supported early and mid-career researchers to network and respond to key areas of research need in cancer care.

The MPCCC's Precision Oncology Program has enabled people with rare, advanced and treatment resistant cancers to participate in cutting edge cancer genomics research, that directly informs clinical management tailored to their individual circumstances. A representative steering group has informed research priorities and directions. Molecular Tumour Boards have convened health professionals and research academics to discuss case management and continue to develop expertise and confidence in applying precision oncology. The Precision Oncology Program seminar series has communicated the latest in research and informed new opportunities across our organisations and disciplines.

The MPCCC has connected the Monash Health Translation Precinct's Clinical Trials Centre and its expertise with a new, emerging clinical trials centre at Latrobe Regional Hospital, enabling patients across Gippsland to participate in clinical trials and access new cancer treatments, closer to where they live.

We have piloted and evaluated innovative models of collaborative care, utilising community-based services and expertise to address gaps in the acute hospital services; and we continue to assess different models for the collection of Patient Reported Outcome Measures and Patient Reported Experience Measures, and will communicate key learnings to our contributing partners by the end of 2021.

In 2020 the MPCCC joined forces with the Victorian Comprehensive Cancer Centre Alliance to form the Victorian COVID19 Cancer Network, an initiative that connected health professionals treating patients with cancer and provided an infrastructure for rapid clinical support, advice and advocacy in response to challenges and opportunities during the COVID-19 pandemic.

Social media, monthly e-newsletters, a website, a networking forum and the MPCCC Annual Report are used to communicate the latest research and clinical advancements and showcase our achievements.

OUR PARTNERS

The MPCCC partnership includes one of Australia’s most research-intensive Universities and a leading provider of healthcare education, public and private hospitals providing care and support to cancer patients across metropolitan and regional Victoria, and a dedicated medical research institute.

The MPCCC is co-funded by the Victorian Government. Moving forward (2021-2025), contributing partners will provide financial and strategic input to the MPCCC. Participating partners share MPCCC’s priorities and collaborate in MPCCC’s research programs. The MPCCC is affiliated with one of Australia’s first accredited Advanced Health Translation Centres and also the Southern Melbourne Integrated Cancer Service, responsible for service improvement across our region.

Our contributing partners



MONASH
University

MonashHealth



Peninsula
Health

Eastern Health

AlfredHealth



HUDSON
INSTITUTE OF MEDICAL RESEARCH

Our participating partners



Cabrini

*Latrobe
Regional Hospital*

Our affiliates



Monash Partners
Academic Health Science Centre

VICS SOUTHERN
MELBOURNE
INTEGRATED
CANCER SERVICE
Together for better cancer care

Our co-funder

**VICTORIAN
CANCER
AGENCY**



MPCCC partner activity: 2020 Snapshot

- MPCCC partner hospitals hosted 38% of cancer clinical trials in Victoria (n=210/544), providing patients with access to the latest investigative treatments¹.
- MPCCC partner hospitals registered 643 newly diagnosed patients and 1082 follow up patients in cancer clinical trials¹.
- Monash University administered \$79.5 million in grants from competitive Commonwealth, State, philanthropic and commercial sources to support cancer research fellows, projects and programs².

Each of MPCCC's partners fosters an active teaching and research culture.

MPCCC clinical partners host two major health translation precincts: **Alfred Medical Research and Education Precinct (AMREP)** and **Monash Health Translation Precinct (MHTP)**. These precincts strengthen links between education and training, basic and clinical research, patient care and innovation to deliver world-class healthcare.

Monash University and the Hudson Institute of Medical Research contribute major technology platforms in pharmaceutical sciences, bio-imaging, histology, proteomics, medical genomics, biobanking and bio-informatics, and curate world-class disease registries to support cancer research discovery and innovation.

Cancer services are comprehensive and incorporate state-of-the-art diagnostic, treatment, supportive care, palliative care and associated allied and community health services for patients, across the cancer care continuum.

For more information about our partners, our community and our research, see Appendices I and II.

¹ Cancer Council Victoria, Cancer Trials Management Scheme *2020 data excludes Cabrini

² Business Intelligence Monash University

PEOPLE AFFECTED BY CANCER IN OUR COMMUNITY

MPCCC's partner health services provide care to over 2.71 million people¹ across south east metropolitan Melbourne, Bass Coast, South Gippsland and the Yarra Ranges.

Our region

The combined catchment area for MPCCC represents 40% of Victoria's population, and includes the state's major population growth corridors. By 2031, the population in our region is expected to grow to over 3.5 million people.

Cancer in Victoria

Cancer is the leading burden of disease in Victoria (see box).²

Cancer incidence in Victoria has steadily increased since 1982, and this growth is predicted to continue. It is estimated that, by 2030-2034, the annual incidence of cancer in Victoria will have increased to over 50,000 cases.

Between 1982 and 2020, five-year survival from cancer in Victoria increased from 49% to 70%. This reflects earlier detection of cancers through screening, reductions in tobacco use, and improvements in treatment and survivorship care. Victoria's sustained investment in cancer research and treatment capabilities is contributing to these outcomes.

Cancer in our region

Five-year survival varies in our region, depending on where you live, with 71% of cancer patients in the southern metropolitan Melbourne surviving for more than 5 years compared to only 65% in Gippsland².

The most common cancers reported in our region in 2019 included genitourinary, breast, colorectal, blood and lung cancers.

Our patients

Age

In 2020 the median age of people living in metropolitan Melbourne was 36 years, which is younger than the rest of Victorian (42.4)³. In the Local Government Areas serviced by MPCCC partner health services, those with the highest median age are the Bass Coast (50), Gippsland (48) and Mornington Peninsula (47), with the lowest being Casey (34), Cardinia (34), Monash (35) and Greater Dandenong (36).³

Cancer in Victoria: 2020 snapshot

- 11,360 deaths (27% of all deaths in Victoria)
- 34,712 Victorians were diagnosed with cancer (~0.5% of the Victorian population)
- There were 7% fewer cancer diagnosis than expected, likely due to the COVID19 pandemic
- Cancer diagnoses are predicted to increase 50% over the next 15 years.
- 47% of cancers diagnosed are in Victorians aged over 70 years
- Five most common cancers: lung, prostate, breast, melanoma and bowel (collectively accounting for 56% of all new cancers and half of all cancer deaths)
- From 1982 to 2020, five-year survival increased from 46% to 70%.
- Aboriginal Victorians are 71% more likely to be diagnosed with cancer

¹ Australian Bureau of Statistics [Regional Population by Local Government Area June 2020](#)

² Victorian Cancer Registry. [Cancer in Victoria Statistics and trends 2020](#)

³ Australian Bureau of Statistics, Reference period 2020. [Regional-population-age-and-sex/2020](#)

Socioeconomic status

The MPCCC region has a diverse socioeconomic spread. The most advantaged regions are Boroondara and Bayside, and the most disadvantaged are Dandenong and Doveton.

Patients born overseas

A total of 37% of patients using MPCCC health services were born overseas. Areas of higher density for migrant populations include Box Hill in the Eastern Health catchment and several Local Government Areas in the Monash Health Catchment.

The top seven languages in the MPCCC catchment are Greek, Mandarin, Italian, Russian, Vietnamese, Hindi and Dutch.

Aboriginal and Torres Strait Islander population

Over 12,000 people across the MPCCC catchment identify as Aboriginal or Torres Strait Islander, representing 25% of Victoria's total Aboriginal Torres Strait Islander populations⁴. The largest groups live in Gippsland, Yarra Ranges and Mornington Peninsula.

OUR AMBITION

Our ambition is to inspire, connect and leverage our research and cancer care communities and resources to facilitate world-class research that is translated to improved cancer outcomes. This will be realised by co-ordinating integrated, cross-organisational cancer research teams that respond to patient needs, connect expertise, drive innovation in current practices and support a future-ready, research-active and competent cancer workforce.

Our vision

To advance cancer care through world class research

Our mission

To accelerate the translation of research findings that improve cancer outcomes.

Our values

Innovation	Generation, development, testing and application of innovations that support world-class cancer research and benefit people with cancer
Collaboration	Positive cross-organisational relationships, cooperation and sharing of information, expertise and resources for cancer research that improve cancer diagnosis, treatment and outcomes
Equity	Improved opportunity for people affected by cancer in our region to access the benefits of research participation
Engagement	Continuous contribution and engagement of stakeholders in collaborative opportunities for cancer research and clinical translation of outcomes into improved cancer care

OUR CHALLENGES AND OPPORTUNITIES

This *MPCCC Strategic Plan 2021-2025* seeks to address the challenges identified by our partner organisations.

Theme	Our challenges	How we can respond	Strategic priorities
Optimising collaborations with non-contributing partner organisations	<p>To nurture relationships and maintain a continuous dialogue with State and Commonwealth Health Departments to communicate achievements and specific needs and challenges for MPCCC.</p> <p>To sustain strong collaborative research relationships with contributing partners.</p> <p>To develop or strengthen mutually beneficial collaborations with organisations currently outside of MPCCC.</p>	<p>Appoint world recognised Executive Director who could bring an extension of the current partnerships and programs of work.</p> <p>Manage expectations through clear and consistent communication.</p>	1, 2
Equitable access to State-of-the-art-cancer research	<p>Keeping pace with new technologies and treatments for all partner health services.</p>	<p>Facilitate “shared access” for MPCCC partners to research platform technologies and other innovations through agreed processes and protocols.</p> <p>Articulate to government the importance of health policies and funding of research and diagnostic technologies to providing equitable patient care across state and national boundaries.</p>	2, 3, 4
Sustainability in a competitive sector	<p>To position MPCCC research teams with competitive advantage for future research funding.</p>	<p>Focus and build on research strengths across the partnership.</p> <p>Identify areas where MPCCC can complement with activities of other Victorian and National cancer research programs.</p> <p>Foster innovative, consumer informed research programs that respond to the needs of the community.</p>	1, 2, 3, 4
Working together	<p>To prevent unproductive competition and duplication of priorities, activities and outcomes within the MPCCC partnership.</p>	<p>Create a clear and transparent leadership and governance structure for MPCCC that drives a functional and effective partnership model.</p>	1
Pushing the boundaries of limited resources	<p>To achieve our expected potential within the resources we have.</p>	<p>Appoint an Executive Director and establish the Executive Function to influence new opportunities for funding.</p>	1
Implementing changes to cancer care	<p>To influence clinical uptake and implementation of MPCCC research programs and outcomes.</p> <p>To effectively communicate with State and Commonwealth Departments of Health about health policies and funding algorithms based on</p>	<p>Support contributing health services to participate in the co-design, development and delivery of MPCCC research programs and outcomes.</p> <p>Ensure appropriate engagement of clinical leaders and influencers in MPCCC activity</p>	1, 2, 3, 4

Theme	Our challenges	How we can respond	Strategic priorities
	the feedback and experience of the organisations constituting MPCCC.	Collaborate with Monash Partners, Victorian Integrated Cancer Services (VICS), VCCC Alliance and others to influence the implementation of research into practice.	
Workforce	Development and retention of a skilled clinical-research workforce that can respond to the needs of our patients.	Provide opportunities for professional development. Create and support multidisciplinary networks for peer learning and support.	2


OUR FUTURE GOVERNANCE MODEL

Strong and appropriate governance is critical to the MPCCC’s future success. Our anticipated future streamlined model recognises the current state of maturity of the MPCCC, the available budget, and the objectives to continue to increase partner engagement with clear lines of accountability.

The continued growth and development of the MPCCC has required regular attention to maintaining a suitable governance model. The MPCCC sought guidance from the Nous Group, an international management consultancy with over 20 years of experience partnering with leaders to shape world-class businesses, to identify a best practice governance model for the MPCCC moving forward. Figure 2 illustrates a proposed model, that is designed to support MPCCC’s continued growth through the 2021-2025 funding period.

The existing MPCCC Governance structure will continue to function until such time that the Executive Director has commenced and the proposed model can be further considered and developed by the contributing parties.

Figure 2. A proposed MPCCC governance model (2021-2025)



Council consists Chief Executives of contributing partner organisations and two consumer representatives. Chief Executive positions cannot be delegated.

Executive function is the Executive Director, Executive Assistant, Chief Operating Officer, and a Communication Manager. The Executive Director reports to the Council.

Consumer Advisory Committee is made up of people affected by cancer, and will provide advice to the Executive function and Research Committee.

Research teams provide structure for members undertaking research. Research teams have a direct reporting line and accountability to the Executive Director, who has oversight of research programs. Each team has two heads, who sit on the **Research Committee**.

If Research teams are large it may be appropriate to include a project steering group that acts as the representative function at this level, with the team managed and reporting to this group.

OUR STAKEHOLDER ENGAGEMENT

Critical to achievement of this Plan is the MPCCC's ability to successfully engage with its multidisciplinary community in a way that supports new research and leads to clinical innovation and improved health outcomes for people with cancer. This outreach will be achieved through the appointment of several new positions, and by continuing to expand existing collaborative network structures.

Executive Director

The appointment of an Executive Director is vital to position the MPCCC for sustainable growth and future success. In addition to directing the MPCCC research teams, the Executive Director will play a critical role in engaging with Victorian Ministers, government departments, partner Chief Executives, industry and other collaborators such as the VCCC Alliance and Cancer Council Victoria.

Consumer and Community Involvement

People with cancer, their carers and the community will provide direction and advice to develop and implement the MPCCC research and education activities.

Communications and Public Relations

Outreach across all of the MPCCC's stakeholder groups will be achieved with the support of a Communications Manager. Responsibilities of this role will include the implementation of new online communications platforms that will ensure stakeholder participation in MPCCC's research, education and networking activities is convenient, practical and achievable for all of our stakeholder groups.

Research Program Co-ordination

MPCCC Program co-ordinators will provide resources to support MPCCC research teams and their activities, and contribute to performance monitoring and evaluation of the Plan.

MPCCC Research and Education Clinical Fellows

MPCCC Research and Education Clinical Fellows will be competitively appointed to each of the contributing partner health services to act as MPCCC champions and facilitate partner-based participation in the MPCCC. The work of the MPCCC Fellows will support aspects of all the MPCCC priorities. These key roles will also link the contributing partners by creating a community of practice. MPCCC Research and Education Clinical Fellows will work within clinical trials centres of our contributing health services and will be an important part of the MPCCC's learning and teaching strategy. The Fellows will also work to facilitate cases being brought to the MPCCC's molecular tumour boards and support the involvement of our wider communities to create opportunities for accelerating research translation.

The MPCCC/VCCC Alliance Action Committee

This Committee identifies research and education initiatives of shared interest to the MPCCC and VCCC Alliance and supports a collaborative response, aiming to reduce duplication of resources and maximise impact for the Victorian cancer community through state-wide initiatives.

The Victorian COVID19 Cancer Taskforce (VCCN)

This joint initiative of MPCCC and the VCCC Alliance aims to support health professionals treating patients with cancer and Victorian policy makers as they adapt to the changing circumstances of health services due to the COVID-19 pandemic. The taskforce of expert members represents a wide range of disciplines including general practice, medical oncology, haematology, radiation oncology, paediatric and geriatric oncology, pharmacy and other specialities, as well as consumers, patient and government representatives.


OUR STRATEGIC PRIORITIES

The *MPCCC Strategic Plan 2021-2025* provides a framework to guide the activities and monitor the progress of the MPCCC over the next four years. The Plan has four integrated strategic priorities, with associated goals and measures of success.

Strategic priorities

PRIORITY 1: GOVERNANCE	Establish a best practice governance model supported by a skilled leadership team to drive the growth and sustainability of the MPCCC, for the benefit of our partners and their patients.
PRIORITY 2: EDUCATION AND COMMUNICATION	Increase awareness of MPCCC and connect stakeholders to research programs and development opportunities
PRIORITY 3: PRECISION CANCER PROGRAM	Build capacity for further world-class innovations in cancer treatment by linking advances in cancer research to patient care
PRIORITY 4: CLINICAL TRIALS	Link clinical trial capabilities across rural, regional and outer metro areas and co-ordinate structures that provide patients with access to novel treatment approaches.

Figure 3: MPCCC Strategic Priorities



PRIORITY 1: GOVERNANCE

Establish a best practice governance model supported by a skilled leadership team to drive the growth and sustainability of the MPCCC, for the benefit of our partners and their patients.

Collaboration between MPCCC's partner organisations and disciplines will increase the quality, capacity and sustainability of cancer research in Victoria. With co-funding from the MPCCC's contributing partners and the Victorian Government, for the first time the MPCCC has an opportunity to further develop its organisational capability and influence and to further support effective collaboration. By investing in its leadership and network support infrastructure the MPCCC will work to synergise, strengthen and accelerate cancer research translation across its partnership and support alignment with the broader Victorian, national and international cancer research agendas, to ensure that all Victorians can access world-class cancer research and care.

Priority 1 activity in the next four years will:

Expand effective collaboration across the MPCCC partners

Increase the influence and impact of MPCCC in the Victorian cancer research context

Position MPCCC to sustain funding beyond 2025

Priority 1 Goals 2021-2024:

1. Establish a best practice governance model that effectively supports the strategy and function of the MPCCC;
2. Support partnerships between metropolitan, regional and rural cancer centres
3. Effectively engage our community to inform and drive MPCCC's collaborative cancer education, precision cancer and clinical trial activities
4. Build consumer participation into every level of MPCCC's governance and work
5. Work collaboratively with the Victorian Government, VCCC Alliance, VICS, Cancer Council Victoria, Monash Partners and others to support a co-ordinated Victorian approach to delivering the Victorian Cancer Plan 2020-2024

Priority 1 Target Outcomes Year 1. By 23 May 2022 there will be

MPCCC leadership and program staff are recruited and appointed

A minimum of six MPCCC/VCCC Alliance Action Committee meetings are convened

A minimum of six Victorian COVID19 Cancer Network Taskforce meetings are hosted

Priority 1 Target Outcomes 2021-2024:

To be finalised on presentation of the year one annual report (May 2022). For example: By May 2025 there will be 10% increase in subscribers to MPCCC social media

A minimum of 15 trained consumer advocates involved in advising and directing MPCCC research activities

4 funded cancer projects demonstrating collaboration across the MPCCC partnership

A commitment for continued investment in MPCCC beyond 2025

Policy Alignment: The Victorian Cancer Plan 2020-2024 Action Area 5.6 Promoting effective collaboration across research organisations, health services, consumers and industry

PRIORITY 2: EDUCATION AND COMMUNICATION

Increase awareness of MPCCC and connect stakeholders to research programs and development opportunities

Ongoing education is critical for all in community including the cancer workforce and consumers, to build skills and knowledge in the latest cancer research technologies and applications. By inspiring a culture of knowledge sharing and peer-to-peer learning, MPCCC will ensure that researchers at all levels of our partner's organisations can quickly adapt to the changing opportunities that emerge through research and respond to the needs and priorities of people affected by cancer. Our approach will focus on harnessing research and clinical expertise that will accelerate the translation of new findings into practice to achieve improvements in outcomes for consumers.

Priority 2 activity in next four years will:

Increase community awareness of and participation in the MPCCC

Support and inspire a workforce culture of cross disciplinary knowledge sharing and peer-to-peer learning

Empower people affected by cancer and their families to make informed choices and inform the future of cancer research and care

Priority 2 Goals 2021-2025

1. Develop and implement a powerful internal and external communications strategy
2. Create opportunities for engagement and networking that support multidisciplinary, cross organisation collaboration and research translation into clinical practice
3. Facilitate access to research education and development programs for people affected by cancer
4. Enable MPCCC partner-wide access to genomics education and development opportunities for the cancer research workforce
5. Drive synergies across Victoria's cancer workforce education, training and development activity (with a focus on genomics and clinical trials) to reduce duplication of resources whilst maximising community benefit

Priority 2 Target Outcomes Year 1. By 23 May 2022 there will be

A minimum of six MPCCC Precision Cancer Seminars convened

A Victorian Precision Cancer Symposium convened in collaboration with the VCCC Alliance

A minimum of ten MPCCC electronic newsletters distributed across the network

Priority 2 Target Outcomes 2022-2025

To be finalised on presentation of the year one annual report (May 2022). For example: By May 2025:

A minimum of 1000 people have participated an MPCCC committee, networking or education event

A minimum of 100 MPCCC contributing partner employees have attended an MPCCC Molecular Tumour Board

All MPCCC contributing partners are conducting cancer education programs for CALD and aboriginal communities

Policy Alignment: The Victorian Cancer Plan 2020-2024, Action area 5: Accelerate translation of research into improved clinical outcomes

PRIORITY 3: PRECISION CANCER PROGRAM

Build capacity for further world-class innovations in cancer treatment by linking advances in cancer research to patient care

Global knowledge of cancer genomics is continuously evolving and so too is our understanding of the applications and benefits of genomics for cancer care. MPCCC partner organisations must adapt to these changing opportunities and facilitate access to the technologies and therapies that will provide the best results for people with cancer.

The MPCCC Precision Cancer Program will continue to build a future-ready community and research hub driving discovery, personalised medicine and improvements in clinical care and outcomes. It will continue to integrate our partners strengths in discovery, translational and clinical research; develop accessible platforms that will support future patient-centred research and clinical care; and advance clinical expertise and experience through interdisciplinary collaborations.

Priority 3 Activity in the next four years will:

Improve partner-wide patient access to integrated precision cancer services

Provide access to the latest in molecular tumour screening technology to patients with difficult to treat cancers

Increase workforce experience and expertise in the clinical application of precision cancer

Sustain and reward an engaged and accessible network of cancer research and clinical leaders

Increase evidence to support implementation of tumour genomic analyses into routine cancer care

Priority 3 Goals 2021-2025:

1. Progress, expand and evaluate the MPCCC Precision Cancer Program
2. Understand the patient experience and health outcomes following participation in the MPCCC Precision Cancer Program
3. Develop an MPCCC Precision Cancer Cohort resource
4. Develop informatics capability across the MPCCC partnership to support precision cancer and identify new research opportunities

Priority 3 Target Outcomes Year 1. By 23 May 2022 there will be

A minimum of 50 patients from MPCCC contributing partners referred for comprehensive tumour profiling

A minimum of six MPCCC Molecular Tumour Board meetings convened

40 cases presented at MPCCC Molecular Tumour Boards across six tumour streams

Priority 3 Target Outcomes 2021-2025:

To be finalised on presentation of the year one annual report (May 2022). For example, by May 2025 there will be:

Double the number of cancer patients treated in MPCCC partner accessing tumour genome profiling tests (from 100 to 200)

MPCCC Molecular Tumour Board data is linked into Multidisciplinary Team Meetings

200 cancer patients have consented to participate in the MPCCC Precision Cancer Cohort resource

Policy Alignment: The Victorian Cancer Plan 2020-2024, Action Area 5.2 Promoting equitable access to emerging therapies, technologies and platforms.

PRIORITY 4: CLINICAL TRIALS

Link clinical trial capabilities across rural, regional and outer metro areas and co-ordinate structures that provide patients with access to novel treatment approaches.

MPCCC will work with contributing partner's clinical trials centres, participating partner health services, people with cancer and large Victorian trials programs like TrialHub, REVITALISE and the VCCC Alliance Clinical Trials Platform to improve patient access to novel targeted cancer treatments through clinical trials.

These activities will recognise and respond to the role MPCCC has to play in facilitating the translation of research to the clinical environment.

Priority 4 activities in the next four years will:

Increase patient participation in cancer clinical trials

Facilitate better access to clinical trials for cancer patients who live in regional and rural areas served by MPCCC partners

Improve workforce awareness of Australian cancer trials available to cancer patients

Reduce barriers for patients to participate in clinical trials, including for CALD, Aboriginal and Torres Strait Islander populations

Link MPCCC partners with funded Clinical Trials projects (eg. TrialHub, REVITALISE and VCCC Clinical Trials Platform) to benefit cancer patients treated in MPCCC Partner hospitals

Priority 4 Goals 2021-2025:

1. Establish accessible systems to link patients to available clinical trials, based on tumour pathological and molecular profiling
2. Link experienced cancer clinical trials teams with emerging regional and outer metro clinical trials teams to provide a supportive mentoring structure
3. Facilitate the use of cancer tele-trials to increase access to and participation in clinical trials for people with cancer

Priority 4 Target Outcomes Year 1. By 23 May 2022 there will be

Two MPCCC Clinical Research and Education Fellows appointed

A minimum of 10 cancer patients considered for a clinical trial or study based on their tumour's genomic profile

Priority 4 Target Outcomes 2022-2024:

To be finalised on presentation of the year one annual report (May 2022). For example, by May 2025 there will be:

5% increase in cancer patients treated across MPCCC health services are recruited to a cancer clinical trial

Policy Alignment: The Victorian Cancer Plan 2020-2024, Action Area 5.1 Improve participation and reduce inequities in access to cancer clinical trials

MEASURING OUR SUCCESS

We have defined Year 1 measures of success for each strategic priority. Metrics for subsequent years continue to develop in consultation with the transitioning MPCCC leadership and will be submitted alongside the 2021-2022 Annual Report. Overarching measures of the success of the MPCCC will keep us focused on our direction and opportunities.

We will know we have succeeded when...

...we have a united and effective consortium, undertaking world-class cancer research informed by patient need

...we have an engaged network of people affected by cancer contributing to our strategic directions and activities

...our research and clinical experts are working together to identify priority research questions and translate research findings into practice

...we have developed and are using world-class platforms for pre-clinical research

...more patients with cancer in our region have access to relevant cancer clinical trials and are benefiting from their participation

...our community recognises the MPCCC brand, equates it with quality cancer research and know how they can get involved

INDICATIVE BUDGET 2021-2025

Revenue	June 2021-May 2022	June 2022-May 2023	June 2023-May 2024	June 2024-May 2025
VCA	\$ 2,000,000	\$ 500,000	\$ 1,000,000	\$ 500,000
Partner co-contributions	\$ 750,000	\$ 750,000	\$ 1,000,000	\$ 1,000,000
	\$ 2,750,000	\$ 1,250,000	\$ 2,000,000	\$ 1,500,000
Personnel Related Expenses				
Staff	\$ 503,997	\$ 981,385	\$ 997,789	\$ 1,007,930
External Contractors	\$ 110,000	\$ 25,000	\$ 25,000	\$ 25,000
Consultancy	\$ 15,000	\$ -	\$ 20,000	\$ 20,000
Overheads & Standard Indirect Costs	\$ 290,072	\$ 559,284	\$ 684,226	\$ 697,148
Total Personnel Related Expenses	\$ 919,069	\$ 1,565,669	\$ 1,727,015	\$ 1,750,078
Direct Program Expenses				
Priority 1: Governance	\$ 17,800	\$ 9,250	\$ 9,600	\$ 9,600
Priority 2: Communication and Education	\$ 15,200	\$ 29,000	\$ 35,500	\$ 35,500
Priority 3: Precision Cancer Program	\$ 68,450	\$ 125,000	\$ 130,000	\$ 130,000
Priority 4: Clinical Trials	\$ 53,000	\$ 330,000	\$ 330,000	\$ 210,000
Total Program Expenditure	\$ 154,450	\$ 493,250	\$ 505,100	\$ 385,100
Total Expenditure for Period	\$ 1,073,519	\$ 2,058,919	\$ 2,232,115	\$ 2,135,178
Balance of funds	\$ 1,676,481	\$ 867,562	\$ 635,447	\$ 269

*Refer to Annual Implementation Plan for detailed costings of each program

APPENDIX I: ABOUT OUR PARTNERS

Our Contributing Partners

Alfred Health

Alfred Health is a leading metropolitan health service in Melbourne, Australia. We pride ourselves on giving our patients and our community the best possible health outcomes by integrating clinical practice with research and education.

Recognised as a national leader in health care, Alfred Health has a commitment to biomedical research. We are also known for excellence in training for medical, nursing, allied health and other support staff. This is further enhanced through partnerships with Monash University, La Trobe University, and several internationally recognised medical research organisations such as the Burnet Institute.

Clinical Cancer research at The Alfred is conducted within Alfred Health Radiation Oncology, Malignant Haematology and Stem Cell Transplantation Service, Victorian Melanoma Service, Endocrinology and Diabetes and Medical Oncology Unit. The Alfred is also a participant of the Victorian Cancer Biobank, is home to the Alfred Medical Research and Education Precinct (AMREP), and includes a branch of the Australian Nucleus Network clinical trials facility.

Eastern Health

Eastern Health is one of Melbourne's largest metropolitan public health systems serving the geographically and culturally diverse community in the eastern and north-eastern parts of Melbourne. Our cancer clinical services are offered at Box Hill, Maroondah and Yarra Ranges (Lilydale) hospitals, comprising expertise in both solid tissue and blood cancers.

Eastern Health is affiliated with Monash University Faculty of Medicine, Nursing and Health Sciences and hosts annually, a vast number of medical, nursing and allied health students from Monash and other universities, such as Deakin. The Eastern Clinical Research Unit (ECRU), as part of Monash University's Eastern Health Clinical School, administers and ensures high activity in clinical trials across the breadth of cancer research programs.

Monash Health

Monash Health is a dynamic health care organisation that successfully integrates best-practice patient care with cutting edge research. With four major inpatient services across a broad geographical area, it is Victoria's largest health care network. Monash Health employs more than 14,000 staff to care for over 1.3 million culturally diverse Victorians, residing within a 2,312 km² catchment area in the south-east of Melbourne.

Cancer Research at Monash Health includes a state-of-the-art 30-bed clinical trials facility headquartered in the Monash Health Translational Precinct (MHTP) at Clayton. This facilitates associated translational research in medical oncology and haematology, capitalising on co-location with advanced technology platforms. There are strong partnerships with leading Monash University research centres including the Monash Institute of Medical Engineering (MIME), Hudson Institute of Medical Research, The School of Clinical Sciences and the Victorian Cancer Biobank. A 230-bed Monash Children's Hospital is one of two tertiary paediatric hospitals in Victoria and has a large paediatric and adolescent cancer service. It is a partner of the Paediatric Integrated Cancer Service (PICS) and shares the emphasis on Cancer Clinical Trials.

Peninsula Health

Peninsula Health is the major health care provider serving the metropolitan and regional areas on Victoria's Mornington Peninsula. With over 900 beds we provide a wide range of services from obstetrics to aged

care, rehabilitation, emergency and intensive care, oncology, psychiatric services and Hospital in the Home. In addition to providing quality, accessible health care services we are a teaching hospital and have a history of contributing to medical research.

Peninsula Health's clinical cancer research is conducted at Frankston Hospital within the Medical Oncology Unit, an Oncology Day Service and Oncology Trials Unit. In 2022, with funding from the Federal Government through the Trial Hub at The Alfred and Cabrini Health, an ambulatory cancer facility will commence at Rosebud with a focus on improving access to cancer clinical trials for the regional community.

Monash University

Monash is a research leader in cancer and blood diseases. The scale and scope of the multidisciplinary research programs is supported by state-of-the-art technology platforms that is conducted across multiple schools, institutes, hospitals and partner organisations, and with engagement of external collaborators.

Cancer researchers at Monash University are investigating many different types of cancers including: prostate, breast, lung, colorectal, head and neck, stomach, pancreatic, liver, brain, ovarian, endometrial, leukaemia, lymphoma, myeloma, oesophageal and bladder.

Monash University's cancer research contributes to innovation through:

- **Understanding the Mechanisms of Cancer:** Cell signalling, Cancer Stem Cells, Tumour Microenvironment, Role of Inflammation and Innate Immunity, Immunology, Metastasis, Hormones, Chemo-resistance
- **Risk Factors and Early Diagnostics:** Occupational and Environmental Risk Factors, Genetics and Epigenetics, Biomarkers and Assays for Early Diagnosis, Inflammatory and Infectious disease risk: e.g. Microbial oncogenesis
- **New Therapeutics:** Antibodies, Structural Biology and Rational Drug Design, Medicinal Chemistry, Molecularly targeted therapeutics, Immunology, Animal models and cell-based screens, Drug candidate optimization, Drug delivery technologies
- **Imaging and Radiation Therapies:** Synchrotron: Microbeam radiation therapy & imaging, Radiation Biology and Radiation therapies, including Brachytherapy, Cell imaging, Medical Imaging (positron emission tomography and magnetic resonance imaging)
- **Clinical Trials and Clinical Research:** Early phase clinical trials, Phase II / III / IV trials, Surgical research, Pathology research, ASPREE Cancer End Points study
- **Epidemiology, Quality of Care and Policy:** Epidemiology and Cancer Registries, Biostatistics – patterns of care, Evidence-based practice, Policy development, Regional health care, Health Economics
- **Supportive and Palliative Care:** Palliative care, Psych-oncology, Patient journey / Survivorship, Outreach and Information dissemination.

Monash Institute of Pharmaceutical Sciences (MIPS)

MIPS is Australia's largest, most experienced and successful group of pharmaceutical scientists. MIPS undertake basic and translational drug discovery, drug delivery and drug development with a focus on oncology, infectious disease, pain and inflammation, neuroscience and metabolic disease. MIPS is a foundation research partner of the Cancer Therapeutics Cooperative Research Centre which is designing new cancer drugs.

Monash Institute of Medical Engineering (MIME)

MIME fosters and coordinates translational med-tech research across Monash University faculties, partner hospitals and collaborating medical research institutions. Our clinician-led research programs focus on major clinical and health system needs, and integrate expertise from across engineering, IT, science, biomedical and clinical research to develop to develop new devices, diagnostics, therapeutics, delivery systems and clinical

tools. We work in close partnership with industry and hospitals to accelerate the development of new technologies through development, trials, commercialisation and adoption. MIME's two major clinical nodes are based at the AMREP and the MHTP.

Monash Biomedical Discovery Institute (BDI)

The Monash Biomedical Discovery Institute (BDI) in the Faculty of Medicine, Nursing and Health Sciences includes a number of discovery programs are organised by disease related themes, including cancer, immunity and infection, development and stem cells, cardiovascular disease, metabolic disease and obesity with the aim of facilitating collaboration across scientific research groups and with clinical partners to accelerate and coordinate the translation of scientific breakthroughs. The Biomedical Discovery Institute will have a focus on increasing interactions with funding agencies, industry, government and philanthropy.

School of Public Health and Preventive Medicine (SPHPM)

Monash University's School of Public Health and Preventative Medicine (SPHPM) is a centre of excellence in registry science. SPHPM has led the development and application of clinical quality registries nationally since the late 1990s and now hosts more than 30 national and state registries. The service is pivotal in linking clinical cancer outcomes to best practice treatment and research priorities. It can also be a tool to inform policy and allocation of health resources. SPHPM is also associated with research focused on prevention of disease including: chronic disease prevention; health promotion; increasing the evidence base of healthcare; improving quality and safety of healthcare; advancing health information technology; improving cost-effectiveness; prolonging disability free survival amongst the elderly; Improving the care of the critically ill and injured; reducing adverse health impacts of the environment and the workplace; and maintaining good research practice, including multicentre ethics and agreements.

Central Clinical School

The Central Clinical School (CCS) is co-located with The Alfred hospital and is a centre for clinical and biomedical research and education, offering undergraduate and postgraduate study programs. CCS is a core hub for translational research and medicine, covering a great breadth of subject areas. CCS's research is highly collaborative, and the School is an integral part of the AMREP where world leaders partner in biomedical and clinical research. With such close links to health care providers, we can rapidly move towards health outcomes in improved patient care.

The Australian Centre for Blood Diseases (ACBD), in Monash's Central Clinical School, aims to provide excellence in the diagnosis and treatment of blood conditions as well as play a leading role in the advancement of knowledge in this increasingly important area of Medicine. The ACBD is affiliated with The Alfred's Haematology Department.

Eastern Health Clinical School

Eastern Health Clinical School (EHCS) is based at Eastern Health's Box Hill Hospital campus, with sites also at Maroondah and Angliss Hospitals and activities across the entirety of Eastern Health. Its four Directorates are Medical Student Programs, Turning Point Alcohol and Drug Centre, Research and Higher Educations, and the Eastern Clinical Research Unit (ECRU). All clinical trials at Eastern Health are conducted through ECRU. A laboratory program in prostate cancer research falls under the auspices of the Research and Higher Education directorate, which also oversees all other aspects of research including non-trial clinical research, laboratory programs in other disciplines, and research higher degree students. The laboratory also supports research in nephrology, vascular medicine, haematology, endocrinology and gastroenterology.

School of Clinical Sciences at Monash Health

The School of Clinical Sciences (SCS) at Monash Health is a vibrant hub of teaching and translational research with a strong collaboration between Monash University and Monash Health. SCS sits within the Faculty of Medicine, Nursing and Health Sciences, Monash University, and provides an innovative approach

to research, education, teaching and clinical practice. The school provides a diverse range of specialities and is at the forefront of medical, clinical/translational research and education.

Cancer research within SCS is diverse and includes a focus on some tumour streams (e.g. haematology, lung, bowel, breast, endometrium, brain, bladder and stomach), investigations of the role that innate immunity, specific proteins and cancer stem cells play in the onset and development of the disease. There are also programs of precision public health, with a focus of cancer risk prediction.

Importantly, our Phase I Clinical Trials Program provides researchers with the potential to translate laboratory findings into new cancer therapies for patients.

Monash University's Technology Platforms

Cancer research programs at Monash University are supported by state-of-the-art research technology platforms, which include (for example):

- The Australian Synchrotron
- Biomedical Proteomics Facility
- Centre for Drug Candidate Optimisation
- Centre for Cancer Genomic Medicine
- FlowCore – Flow Cytometry Core Facility
- High Content Cellomics Screening Facility
- High Throughput Protein Production Facility
- MHTP Medical Genomics Facility
- Micromon Genomics
- Monash Biomedical Imaging
- Monash Genome Modification Platform
- Monash Histology Platform
- Monash Molecular Crystallisation Facility
- Monash Animal Research Platform and Fish Core Facility
- Monash Antibody Technologies Facility, and
- Monash Micro Imaging.

Hudson Institute of Medical Research

Hudson Institute of Medical Research is one of Australia's top medical research institutes, specialising in driving innovative, cutting-edge research towards improved prevention, diagnosis and treatments for our greatest health challenges.

Our world-class scientists and clinicians are at the forefront of discovery and translational research, striving to improve health and quality of life across the entire lifespan by advancing healthcare through an increased understanding of disease and its diagnosis, treatment and prevention. Our excellence in biology, medicine and biotechnology is strengthened by the Institute's diverse, multidisciplinary research environment which fosters collaboration and creates opportunities for unique insights and innovation.

Scientists working in the Hudson Institute's Centre for Cancer Research undertake basic research into the molecular mechanisms underlying both adult and paediatric tumour initiation and development. Bolstered

by a state-of-the-art Functional Genomics Centre, intense efforts are underway to identify and develop novel therapies using innovative patient derived pre-clinical models.

Our Participating Partners

Cabrini Health

As one of the country's largest private providers, Cabrini Health is a leader in comprehensive cancer care. Cabrini's integrated services include diagnostics, surgical care, radiology and chemotherapy, immunotherapy, pastoral care, and palliative and supportive care.

Research is carried out in surgery, medical oncology and haematology, psycho-oncology and palliative care as part of the Cabrini Institute. Established in 1999, Cabrini Research (nee Institute) is the collective name for the numerous researchers and education providers who work at Cabrini. It includes the Cabrini Monash Clinical School, the Cabrini Monash University Department of Surgery, the Monash Department of Clinical Epidemiology at Cabrini Hospital, the Szalmuk Family Department of Medical Oncology, the Cabrini Centre for Nursing Research, the Szalmuk Family Psycho-oncology Unit, the Allied Health Research Unit, the Cabrini Human Research Ethics Committee, and the community education program *Let's Beat Bowel Cancer*.

In 2019 Cabrini received \$6 million that will enable the establishment of a new Institute of Cancer at Cabrini Malvern, allowing researchers and clinicians to work together towards life-saving breakthroughs.

Epworth Healthcare

Epworth Healthcare is Victoria's largest not-for-profit private hospital group, and an innovator in Australia's health system, embracing the latest evidence-based medicine to pioneer treatments and services for our patients. Epworth's Cancer Services Clinical Institute focuses on the diagnosis, treatment and care of patients with cancer, and includes a new academic unit at Epworth Freemasons to provide research, clinical and teaching leadership in molecular oncology and cancer immunology within the University of Melbourne.

Latrobe Regional Hospital

The Gippsland Cancer Care Centre (GCCC) at Latrobe Regional Hospital provides comprehensive cancer care services including chemotherapy, radiotherapy and specialist consulting and support services. Radiation oncology services are delivered by Gippsland Radiation Oncology which is a satellite service of Alfred Health Radiation Oncology. The GCCC employs an experienced, multi-disciplinary team which is committed to a patient-centred model of care.

APPENDIX II: OUR RESEARCH

MPCCC partners provide high-quality, practice-relevant research for translation to hospital and community clinical settings. The success of our clinical research is underpinned by excellence and innovation in discovery science (drug discovery and development, studies of disease progression, biomedical research) and public health and health services research (preventive medicine, health economics and health outcomes).

Co-location of research organisations and health services within the AMREP and MHTP and the development of research facilities within the private health sector, link clinical care with research. The strong links between our clinical and research partners encourage rapid translation of research into patient care and identify emerging health priorities for future research activity.

Discovery research

Monash University's discovery science is internationally recognised in the fields of pharmaceutical sciences, immunology, structural biology and stem cells. The Biomedicine Discovery Institute (BDI), Monash Institute of Pharmaceutical Sciences and the Australian Centre for Blood Diseases, all feature major research programs undertaking world-class cancer research. The University's infrastructure and focus on building partnerships with clinical services, government and industry has enabled ARC Centres of Excellence in Advanced Molecular Imaging and in Convergent Bio-Nano Science and Technology, and major contributions to the Cancer Therapeutics CRC.

MPCCC seeks to link and leverage this infrastructure and expertise along with cancer research contributions from Monash Institute of Medical Engineering (MIME) and other University departments to support new, innovative and patient driven cancer research across the partnership.

Collaborative interactions between Monash University and other MPCCC members, will play a key role in development of new precision medicine approaches.

Hudson Institute's diverse, multidisciplinary research environment, also provides outstanding opportunities for high-impact discovery research. Scientists working in the Hudson Institute's Centre for Research undertake basic research into the molecular mechanisms underlying both adult and paediatric tumour initiation and development. This year an application led by Monash University (Hudson Institute), received a \$9.6 million award from the MRFF to establish the Victorian Paediatric Cancer Consortium (VPCC), that will leverage the unique research expertise and clinical capabilities across the Monash and Parkville precincts. VPCC is a new multi-institutional partnership which will focus on discovery research projects, including next-generation precision oncology, tumour immunotherapy and epigenomics. The collaboration aims to make a difference for the thousands of Australian kids each year facing a cancer diagnosis.

Strategic initiatives in data sharing, led by Monash Partners Academic Health Science Centre, will enable MPCCC to build its cancer research capacity, strengthening our contribution to the field of genomics to inform precision medicine, and filling gaps in bioinformatics and clinical pathology to support laboratory sciences.

Clinical research

MPCCC's clinical research is led mainly by clinician scientists who are integrated into MPCCC's partner health services. Strategic recruitment of clinician–scientists helps MPCCC to align its clinical research efforts with the needs of patients.

MPCCC is acknowledged for its research excellence in malignant haematology. Monash Health is internationally recognised as a myelodysplasia centre of excellence, and The Alfred is to be the site of Australia's first specialist blood cancer centre, the Australian Cancer Research Foundation Blood Cancer

Therapeutics Centre. Available radiation therapy technologies in the region include stereotactic ablative body radiation therapy (SABR) and brachytherapy.

Our health services provide over 1600 cancer patients with access to over 200 cancer clinical trials open at our sites each year, with a focus on Phase III studies investigating new cancer treatments or combinations of treatments. In recent years, growth in investigator-led Phase I trials has occurred at Monash Health and Alfred Health and opportunities exist at other partner hospitals, with the development of clinical facilities and trials managers/co-ordinators. Investment in these resources will be critical to the future development of early phase clinical trials, providing access to leading technologies in cancer therapeutics for Victorians.

Public health and health services research

MPCCC partners conduct large epidemiological studies, provide data management for clinical trials and registries, and coordinate evidence synthesis to inform clinical practice and policy.

MPCCC is internationally regarded for its leadership in clinical cancer registries through Monash University's Department of Epidemiology and Preventive Medicine, which has developed and manages dozens of internationally recognised clinical quality registries including:

- Prostate Cancer Outcomes Registry – Victoria (PCOR-Vic) and Prostate Cancer Outcomes Registry – ANZ (PCOR-ANZ)
- International Prostate Cancer Compare-and-Reduce-Variation Registry (co-headed with the University of California, Los Angeles (UCLA) and in partnership with dozens of prostate cancer registries in North America and Europe)
- Victorian Lung Cancer Registry (VLCR)
- Upper Gastrointestinal Cancer Registry (UGICR)
- National Gynae-Oncology Registry (NGOR)
- Myeloma and Related Diseases Registry (MRDR)
- Lymphoma and Related Diseases Registry (LaRDR)
- Cabrini Monash colorectal neoplasia database
- Bi-National Colorectal Cancer Audit (BCCA)
- Thyroid Cancer Clinical Quality Registry
- Australian Aplastic Anaemia Registry.

APPENDIX IV: ABBREVIATIONS

Abbreviation	Meaning
ACBD	Australian Centre for Blood Diseases
AHSC	Academic Health Science Centre
AMREP	Alfred Medical Research and Education Precinct
AYA	Adolescent and young adult
BDI	Biomedicine Discovery Institute, Monash University
CCS	Central Clinical School
ECRU	Eastern Clinical Research Unit
EHCS	Eastern Health Clinical School
GCCC	Gippsland Cancer Care Centre
KPI	Key Performance Indicator
MDM	Multidisciplinary team meeting
MHTP	Monash Health Translational Precinct
MIPS	Monash Institute of Pharmaceutical Sciences
MIME	Monash Institute of Medical Engineering
MPCCC	Monash Partners Comprehensive Cancer Consortium
MTB	Molecular Tumour Board
MTM	Multi-disciplinary Team Meeting
PICS	Paediatric Integrated Cancer Service
PCP	Precision Cancer Program
PHN	Primary Health Network
SABR	stereotactic ablative body radiation therapy
SCS	School of Clinical Sciences at Monash Health
SMICS	Southern Melbourne Integrated Cancer Service
SPHPM	School of Public Health and Preventive Medicine
The Alfred	The Alfred Hospital, Alfred Health
UCLA	University of California
VCCC Alliance	Victorian Comprehensive Cancer Centre Alliance
VICS	Victorian Integrated Cancer Services
VPCC	Victorian Paediatric Cancer Consortium